METIS: Pivotal open-label randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).

The METIS trial is designed to investigate the efficacy of the NovoTTF-100M device in treating patients non-small cell lung cancer (NSCLC) with metastases to the brain. The eligible subjects must have 1 inoperable brain metastasis or 2-10 brain lesions and must be able to carry the NovoTTF-100M device. Subjects enrolled in the treatment arm of the study will wear the device for at least 18 hours a day, on average, and have study visits roughly every 2 months for 10-15 months. For additional information regarding this clinical trial visit https://www.novocuretrial.com/metis/

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Lung cancer - non-small cell,Metastatic brain tumor
• Age: Between 18 Years - 99 Years
• Gender: All